Grey Matter Neurosciences is a neurotechnology firm developing new medical devices and drug-device combinations to treat age-related brain illnesses like dementia.
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.
HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.
AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.
Spero Analytics is an IoT startup which builds and deploys wireless mesh networks specifically designed for continuous environmental monitoring in remote facilities and off-grid areas. Our sensor arrays can scale up to 100 nodes for a single gateway, cover hundreds of square kilometers, adapt to any type of structural or gas sensor, and require no telecommunications infrastructure to operate. Most importantly, they reduce the burden on maintenance staff as the network is configured to reorganize itself in case any single node goes offline and it can operate in extremely cold climates given the adaptive power savings features built into the system. Our core focus is on automated greenhouse gas monitoring in landfills, having installed sensor arrays at two waste management sites in Ontario. As part of our push to expand to other sectors, we are currently collaborating with Environment Canada to adapt our network to carry out passive greenhouse gas monitoring in petroleum facilities with the aim of producing accurate emission inventories and precise leak detection. We will also be undertaking a Proof-of-Concept project to assess our network's suitability for underground geotechnical hazard monitoring in potash mines. To-date, we have raised $210,000, secured 4 design partners, made sales to Environment Canada and a rainwater harvesting developer in Mexico, and intend on expanding the size of our team to aggressively pursue market entry. Our mission is to become the industry standard for environmental monitoring in remote areas with limited infrastructure.
Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.
Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.
NerveX has developed ANIMO, the adaptive neural implant for modulation and observation. ANIMO is a vessel to implant our proprietary machine learning and responsive electrical neuromodulation technology to repair and augment the nervous system.
Genetics Adviser is a web application that helps the patients to access counseling content and provides genetics health services.
Mazlite is a developer of an industrial IoT platform focused on spray monitoring and digitization in hazardous environments. The company provides unique hardware sensors and web-based software that facilitate real-time analytics and cloud-based data management. This technology is particularly beneficial for industries such as automotive paint and pharmaceuticals, allowing manufacturers to monitor spray applications effectively. By utilizing a physics-based artificial intelligence system, Mazlite enables manufacturers to identify and resolve product quality issues, enhance sustainability, and reduce material and energy waste, ultimately minimizing scraps and repairs.
Damona Pharmaceuticals is a pre-clinical pharmaceutical company treats and prevents cognitive deficits in a variety of brain disorders and during aging.
Damona Pharmaceuticals is a pre-clinical pharmaceutical company treats and prevents cognitive deficits in a variety of brain disorders and during aging.
Pearl Interactives specializes in creating interactive media tailored for children of all abilities, focusing on wellness, play, and learning. The company has developed a unique platform that includes its flagship product, Bootle Blast, which combines innovative mixed reality technology with engaging video game experiences. This system targets children and youth with neuromotor conditions, facilitating exercises that aim to improve their functional abilities. Additionally, the platform incorporates real-life musical instruments and touch-free interactive games, promoting shared musical play while also helping to alleviate anxiety. Through these offerings, Pearl Interactives strives to foster an inclusive environment that enhances the developmental opportunities for children.
Tabiat operates a software-as-a-service (SaaS) platform that specializes in artificial intelligence-driven remote patient monitoring. The platform is designed to enhance patient outcomes by providing actionable insights that aid clinicians in their decision-making processes. By delivering timely and relevant data, Tabiat enables healthcare providers to effectively assess the condition of multiple patients simultaneously, allowing them to focus on those who require immediate attention. This not only improves the quality of care but also helps to reduce hospitalization costs while creating additional revenue opportunities for healthcare professionals.
PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.
PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.
Quantum Bridge is dedicated to enhancing security for organizations that require the protection of highly confidential and classified information. The company develops proprietary software and quantum repeater hardware aimed at improving quantum communications. Its focus is on the commercialization of quantum and quantum-inspired products, which include secure communication tools and a distributed symmetric key exchange system. These innovations are designed to ensure that communication remains quantum-safe, thereby reinforcing network and endpoint security. By providing solutions that enhance resilience in existing networks, Quantum Bridge aims to meet the growing demand for unbreakable security in today's digital landscape.
Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.
Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.
Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in developing artificial intelligence solutions to enhance drug discovery and the creation of therapies for cancer. Its innovative platform utilizes AI, computer vision, and high-content screening to analyze phenotypes in complex disease models, such as high-content co-culture and three-dimensional assays. By focusing on the tumor stroma, Phenomic AI aims to optimize the discovery and development of new medicines, streamlining the process for pharmaceutical companies to identify potential drug candidates more effectively.
Patient care is becoming increasingly complex, requiring coordination and collaboration between multiple providers across different departments and specialties. However, hospitals and other healthcare settings have yet to catch up with these demands. The primary method of reaching providers is still through switchboards and pagers in hospitals. This ineffective modality leads to delays in patient care and poor patient outcomes. To take matters into their own hands, clinicians have resorted to non-secure smartphone apps such as WhatsApp and iMessage. However, this puts patient personal health information at risk, and creates enormous medico-legal liability for providers and hospitals.
Phycus Biotechnologies Inc. is a Toronto-based company founded in 2017 that specializes in producing ingredients for the cosmetics and personal care industries, including bioglycolic acid and AHA ferment products. Additionally, the company operates a bio-conversion platform that focuses on capturing and converting carbon dioxide from large-scale emitters into valuable chemical building blocks. By employing microbial technology and metabolic engineering techniques, Phycus aims to provide sustainable alternatives for recycling carbon dioxide into fuels and chemicals. This innovative approach not only supports various industrial applications but also contributes to reducing the overall greenhouse gas footprint, aligning with environmental sustainability goals.
Reeddi is a climate technology company focused on creating innovative solutions for sustainable, clean, and affordable electricity. The company targets energy-poor regions, aiming to provide electricity where it is currently unavailable. Reeddi's technology is designed to generate, distribute, and store clean energy, delivering both alternating current (AC) and direct current (DC). This versatility allows their devices to power a range of applications, from mobile phones to household electronics, thereby enhancing energy access for individuals, households, and businesses. By offering an alternative to fuel-based electricity generation, Reeddi seeks to mitigate the health and environmental risks associated with traditional energy sources in operating communities.
Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.
ODAIA is a company that has developed an AI-powered Customer Data Platform specifically for the Life Sciences industry. This innovative platform integrates process mining, customer journey mapping, and artificial intelligence to provide commercial insights and automate processes. By leveraging data analysis, ODAIA's solution enables pharmaceutical commercial teams to enhance personalized selling and ensure that therapeutics reach the patients who require them. The platform aims to streamline decision-making and improve the effectiveness of commercial strategies in the healthcare sector.
CoHealth is a content creation and distribution platform tailored for health organizations, including healthcare providers and systems. The platform facilitates the development and dissemination of health-related content, enabling these organizations to effectively reach health consumers. It offers features such as hospital information, medication reminders, and personalized task recommendations through a collaboration between personal health managers and healthcare providers. By creating customized digital care pathways for various health conditions, CoHealth ensures that patients receive comprehensive aftercare support following their hospital discharge.
Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.
Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.
Flybits is the leading customer experience platform for the financial services sector, delivering personalization at scale. With the most advanced capabilities in the market, its enterprise-level solution brings relevant content, products, offers, and information to a bank’s digital channels based on what each individual customer needs in the moments that matter. With Flybits, banks are able to design, launch, and measure data-driven consumer experiences that deliver the right information to the right customer at the right time, while preserving their privacy. www.flybits.com
Cohesys develops innovative surgical adhesives inspired by nature, specifically designed for craniomaxillofacial (CMF) fracture fixation. The company's biodegradable bone tape offers a flexible and resorbable solution that can effectively replace traditional titanium screws. By streamlining the fracture fixation process, Cohesys' technology aims to enhance patient outcomes and reduce the risks associated with bone fractures. Its advanced adhesive system contributes to safer and faster surgical procedures, ultimately improving the overall efficiency of treatment for facial fractures.
Mutuo Health Solutions specializes in developing artificial intelligence technology to enhance healthcare communication. The company offers a medical device that captures dialogues between patients and clinicians using any microphone. This AI-driven solution employs speech recognition and natural language processing to automatically generate clinical notes and suggest actions for electronic medical records in real time. By streamlining the documentation process, Mutuo Health Solutions allows medical professionals to concentrate more on patient care, thereby improving overall healthcare efficiency and effectiveness.
Bitnobi is a software company focused on designing and developing a data-sharing platform primarily for the healthcare and finance sectors. The platform enables secure and privacy-protected access to big data, eliminating the need to create multiple copies of source data. By centering on launching data jobs for end users, Bitnobi facilitates efficient data sharing while maintaining data integrity and security. The company's services encompass data management, cloud computing, and cybersecurity, providing comprehensive solutions tailored to the specific needs of its clients. An online inquiry form is available on their website for potential customers seeking more information.
Micellae Delivery Systems is a pharmaceutical manufacturing company specializing in innovative drug delivery systems aimed at enhancing the solubility and bioavailability of fat-soluble compounds, particularly cannabinoids. The company has developed proprietary formulation platforms that facilitate the creation of various dosage forms, including liquids, concentrates, gels, and powders. These formulations cater to a diverse range of applications in medical and recreational cannabis, as well as in the pharmaceutical, nutraceutical, and cosmetic sectors. By focusing on cost-effective and sustainable technologies, Micellae Delivery Systems provides clients with healthier and safer options for cannabis delivery.
Lorica's cutting-edge encryption technologies enable secure and privacy-preserving data analytics in the cloud at enterprise scale. Our team of top scientists, engineers and business leaders have designed solutions that allow enterprises to interact with encrypted data across their entire value chain – on premises, in the cloud, across 3rd parties – without ever exposing it to risk. We are on a mission to empower enterprise organizations to securely generate insights, collaborate seamlessly, accelerate innovation and ensure regulatory compliance. Lorica unlocks the value of all data and provides trusted tools for data analytics that protects privacy and intellectual property in a digital-first world.
NURO is the manufacturer of the NUOS, PAD, KOMPOS and MENTIS surgery-free neurological platforms. For more information, please visit www.nuro.world.
Non Equity Assistance in 2018
Appulse Power Inc. is a semiconductor design company based in Toronto, Canada, specializing in application-specific integrated circuits (ASIC) for power management. Founded in 2015 and later acquired by The Silanna Group Pty. Ltd. in 2018, Appulse Power focuses on innovative AC/DC power conversion technologies tailored for the Internet of Things and smart energy markets. The company's products aim to enhance efficiency, reduce costs, and minimize the physical size of power supplies compared to existing solutions. By addressing the challenges associated with traditional AC/DC converters, Appulse Power enables the consolidation of electronic device chargers into a single, compact unit, significantly lowering size and power loss.
Upchain is a provider of cloud-based product lifecycle management (PLM) and product data management (PDM) solutions, established in 2015. The company aims to transform the way PLM is approached by making it more accessible to all participants in the supply chain, rather than focusing solely on large multinational corporations. Upchain's software facilitates collaboration across decentralized product value chains, offering features such as item management, version control, change management, bills of materials management, file compliance, and integration with computer-aided design tools. This comprehensive approach enables manufacturers operating within complex value chains to enhance revenue, reduce costs, and improve product quality, thereby streamlining the entire lifecycle from initial design to final assembly.
Dalriada Therapeutics Inc. is a Canadian company based in Mississauga, established in 2016. It specializes in the development of novel small molecule inhibitors targeting various medical conditions, including oncology, pain modulation, and neurodegenerative and neuroinflammatory disorders. The company employs a TURN-KEY model that integrates research and development with business strategy and intellectual property management, thereby supporting global innovators in the pharmaceutical industry.
Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.
Bitnobi is a software company focused on designing and developing a data-sharing platform primarily for the healthcare and finance sectors. The platform enables secure and privacy-protected access to big data, eliminating the need to create multiple copies of source data. By centering on launching data jobs for end users, Bitnobi facilitates efficient data sharing while maintaining data integrity and security. The company's services encompass data management, cloud computing, and cybersecurity, providing comprehensive solutions tailored to the specific needs of its clients. An online inquiry form is available on their website for potential customers seeking more information.
Patient care is becoming increasingly complex, requiring coordination and collaboration between multiple providers across different departments and specialties. However, hospitals and other healthcare settings have yet to catch up with these demands. The primary method of reaching providers is still through switchboards and pagers in hospitals. This ineffective modality leads to delays in patient care and poor patient outcomes. To take matters into their own hands, clinicians have resorted to non-secure smartphone apps such as WhatsApp and iMessage. However, this puts patient personal health information at risk, and creates enormous medico-legal liability for providers and hospitals.
Structura Biotechnology specializes in developing a cryo-electron microscopy image analysis platform that enhances the study of biological systems. The platform employs machine learning technology to facilitate the detailed analysis and 3D reconstruction of atomic structures of proteins, biomolecule complexes, and viruses. This capability allows researchers to investigate membrane proteins, ion channels, G protein-coupled receptors, and drug targets with ligands bound. By providing advanced tools for cryo-electron microscopy data analysis, Structura Biotechnology supports healthcare professionals in creating new medicines and improving drug development processes.
Appulse Power Inc. is a semiconductor design company based in Toronto, Canada, specializing in application-specific integrated circuits (ASIC) for power management. Founded in 2015 and later acquired by The Silanna Group Pty. Ltd. in 2018, Appulse Power focuses on innovative AC/DC power conversion technologies tailored for the Internet of Things and smart energy markets. The company's products aim to enhance efficiency, reduce costs, and minimize the physical size of power supplies compared to existing solutions. By addressing the challenges associated with traditional AC/DC converters, Appulse Power enables the consolidation of electronic device chargers into a single, compact unit, significantly lowering size and power loss.
QD Solar Inc. is a Canadian company based in Toronto that specializes in the development of advanced photovoltaic cells utilizing colloidal quantum dot technology. Founded in 2014 as a spinoff from the University of Toronto, QD Solar combines silicon solar cells with infrared solar cells in a hybrid architecture. This innovative approach allows the company to capture a broader range of the solar spectrum compared to traditional silicon cells alone. By enhancing the efficiency of solar energy harvesting, QD Solar aims to address the competitive pressures in the solar photovoltaic market, where differentiation through improved performance at competitive costs is essential. The company's technology promotes sustainable development and aims to increase the adoption of renewable energy sources.
Patient care is becoming increasingly complex, requiring coordination and collaboration between multiple providers across different departments and specialties. However, hospitals and other healthcare settings have yet to catch up with these demands. The primary method of reaching providers is still through switchboards and pagers in hospitals. This ineffective modality leads to delays in patient care and poor patient outcomes. To take matters into their own hands, clinicians have resorted to non-secure smartphone apps such as WhatsApp and iMessage. However, this puts patient personal health information at risk, and creates enormous medico-legal liability for providers and hospitals.
Fibrocor Therapeutics L.P. is a biotechnology company based in Toronto, Canada, established in 2017. The company specializes in the development of tissue-specific therapeutics aimed at addressing the underlying causes of fibrotic diseases affecting the kidneys and other organs. Fibrocor focuses on identifying and targeting critical pathways involved in the fibrogenic process, utilizing patient-derived tissue samples to uncover novel disease targets. The company has advanced a lead program and has partnered with Evotec to facilitate the development of innovative therapeutic molecules.
LegUp Computing Inc. is a Toronto-based company that develops a cloud platform enabling software developers to program, deploy, scale, and manage field-programmable gate array (FPGA) devices. Founded in 2015 by a team including Dr. Andrew Canis and Professor Jason Anderson, the platform originated from research at the University of Toronto and focuses on providing a novel programming model for threaded C/C++ software. This model allows for efficient processing of low-latency database, real-time analytics, and machine learning workloads by leveraging FPGA devices connected to high-bandwidth networks. LegUp Computing aims to facilitate the acceleration of high-performance applications, thereby enhancing the capabilities of developers working with cloud-based and embedded compute systems. The company operates as a subsidiary of Microchip Technology Incorporated.
HippoCamera is an online application aimed at enhancing the memory recall of older adults through engaging reminiscence activities. The platform employs a unique approach that simulates the function of the hippocampus, a critical area of the brain involved in memory processing. By combining enjoyable activities with proven cognitive benefits, HippoCamera helps users improve their ability to recall and remember significant events from their lives, ultimately promoting cognitive health and well-being among the elderly.
Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.
Advances in medical science have introduced the era of personalized medicine for organs. XOR Labs Toronto is a pioneer in this field. We are changing the face of organ transplantation by exponentially increasing the number of donated lungs available for transplantation around the world.
Purchs is an omnichannel platform that facilitates efficient sourcing and billing for merchants by integrating conversational commerce and artificial intelligence. Merchants can effortlessly complete transactions through text by scanning a Product UPC code with their smartphones, eliminating the need for logins or traditional checkout processes. For vendors, Purchs provides a comprehensive e-commerce solution tailored for B2B retail sales, allowing them to list products at custom prices, manage inventory and deliveries, and automate payment processes, all from a single platform. Additionally, the platform simplifies wholesale distribution and direct-to-store delivery, helping clients reduce both distribution costs and their carbon footprint.
Radialis develops an organ-targeted positron emission tomography (PET) imaging system aimed at providing high-definition and low-dose imaging solutions for oncology, neurology, and cardiology. Its technology significantly enhances the efficiency of detecting radiotracers compared to conventional PET systems, which allows for improved cancer detection. The system has received broad FDA clearance in the United States for imaging and measuring injected positron-emitting radiopharmaceuticals. Currently, the leading application of this technology is in the high-resolution imaging of primary solid tumors, assisting in treatment planning as a complement to traditional staging PET/CT without requiring additional radiotracer. Furthermore, Radialis is exploring opportunities for early detection of cancer and Alzheimer's disease using low-dose imaging techniques in high-risk populations.
Knitt Labs is a Toronto-based technology start-up that aims to address energy waste by transforming how power is utilized and managed. The company has developed innovative technology that leverages big data to optimize electricity consumption, helping clients reduce energy waste and save on costs. By integrating Internet of Things (IoT) devices, Knitt Labs enables users to gain better insights into their energy usage, ultimately redefining individual power management practices.
Crowd2Know operates in the area of stakeholder engagement. We bring organizations operating in urban development closer to their customers, citizens and end users by providing a platform for listening, analyzing, and effectively communicating with each other. We achieve this through a systematic process using a suite of software products and expert services that facilitate the analysis of social media, project documents, and other records. Using our urban infrastructure knowledge base and set of analysis algorithms we provide a real-time mapping of stakeholders, discussion topics, and relative alignment of opinions which drive consistent recommendations for decision makers.
Blue J is a developer of a legal research platform that aims to predict court outcomes, enhancing the efficiency of legal professionals. By employing machine learning and artificial intelligence, the platform analyzes historical judicial decisions to identify patterns that can forecast the results of future cases. This capability allows legal practitioners to utilize relevant case law effectively, ultimately saving time and reducing costs associated with legal research. The platform is designed to improve productivity, enabling users to concentrate on higher-value tasks within their practice.
Onyx Motion is a developer of sports coaching applications for apple and android smartwatches.
PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.
Non Equity Assistance in 2016
FlowJEM specializes in the development of polymer microfluidic technology aimed at the rapid and cost-effective prototyping of microfluidic devices. The company provides high-quality plastic microfluidic components made from various thermoplastic materials, ensuring compatibility with specific chemical requirements as well as optical transparency and temperature stability. FlowJEM's technology is tailored for researchers and engineers in the microfluidics field, facilitating the creation of robust devices for diverse applications.
ScarX Therapeutics (ScarX) is a biotechnology company that discovers and develops innovative treatments for dermal scarring (fibrosis). ScarX’s lead candidate, SCX-001, will be the first prescription cream for the reduction of post-surgical scarring. ScarX is committed to improving the lives of surgical patients worldwide by providing therapies that prevent and reduce the occurrence of disfiguring, uncomfortable or cosmetically unattractive surgical scars. ScarX was established in 2012 through partnerships with Toronto’s Hospital for Sick Children (Sick Kids), MaRS Innovation and MaRS Discovery District. ScarX's dermal scar technology is based on over 15 years of research conducted by Dr. Benjamin Alman as a senior scientist and head of Orthopedic Surgery at SickKids. Dr. Alman discovered that nefopam, a known active pharmaceutical ingredient (API), is an effective anti-scarring agent. ScarX immediately developed a re-purposing strategy to advance nefopam for scar treatment and reduction, and has recently competed preclinical studies. The company is now poised to take SX-001 into Phase I/IIa clinical trial. Every year, more than 100 million people in developed countries worldwide experience dermal scarring resulting from surgery. Scarring can have significant physical and psychological implications, from reduced function to disfigurement and emotional trauma. Despite this significant unmet need, no clinically-proven prescription anti-scarring treatment is available on the market today. In the U.S. alone, the estimated market potential for an effective anti-scarring treatment is over $4 billion USD annually. ScarX is currently focused on developing its topical agent, SCX-001, to reduce scarring following cosmetic and reconstructive plastic surgeries. Reconstructive and cosmetic surgery market segments have the advantage of representing a significant portion of the overall market and lend themselves to a niche marketing approach (<10,000 plastic surgeons and aesthetic dermatologists in the U.S. and Canada). Overall, ScarX estimates the combined market value in the U.S. for these two market segments to be in the range of $2.0 - $2.5 billion USD annually.
WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.
AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.
CoHealth is a content creation and distribution platform tailored for health organizations, including healthcare providers and systems. The platform facilitates the development and dissemination of health-related content, enabling these organizations to effectively reach health consumers. It offers features such as hospital information, medication reminders, and personalized task recommendations through a collaboration between personal health managers and healthcare providers. By creating customized digital care pathways for various health conditions, CoHealth ensures that patients receive comprehensive aftercare support following their hospital discharge.
Nuralogix specializes in healthcare analytics by leveraging its patented technology, Transdermal Optical Imaging (TOI™), which extracts facial blood flow information using a conventional video camera. The company's flagship app, Anura™, allows users to monitor their health without the need for traditional wearables or cuffs, making it the first contactless application for measuring blood pressure. Anura™ not only measures blood pressure but also assesses various physiological and psychological indicators, such as heart rate, stress levels, body mass index, and cardiovascular disease risks, all with medical-grade accuracy. This innovative approach enables individuals to track their health conveniently and efficiently, enhancing overall well-being.
Ardra is a startup based on technology developed at the University of Toronto. Their technology uses model-guided metabolic engineering and synthetic biology to develop biocatalysts for the production of specialty chemicals from renewable resources. Their current target is the cosmetics industry, which uses $2.6 billion worth of petroleum chemicals in a variety of products.
Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation, and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein.
LegWorks, Inc. is a social enterprise based in Buffalo, New York, that specializes in designing and manufacturing prosthetic knee joints and complete prosthetic leg solutions for lower-limb amputees globally. Founded in 2013, the company aims to provide these essential components regardless of the amputees' location, social status, or financial means. LegWorks implements a tiered pricing strategy to create accessible options across different markets, ensuring that its products reach both developed and developing regions. The company's prosthetic knee joint features a locking mechanism that prevents bending, facilitating mobility and promoting independence for users, enabling them to navigate their daily lives with confidence.
Syncadian Inc.’s first product was a mobile app helping soldiers in the Canadian military to prevent jetlag. The company is continuing to develop software in the fatigue modelling and management space, exploring possible applications for shift workers, military personnel, cancer patients and others. Syncadian’s vision is to develop fatigue solutions, enabling companies to decrease fatigue related errors and increase productivity, and enabling individuals to monitor sleep quality and quantity and optimize their sleep patterns.
ChipCare’s mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. The envisioned product entails two components: handheld reader and disposable test slide. The revenue will mainly be generated from sales of disposable test slides (consumables). Our proprietary detection technique enables testing of multiple diseases from a single drop of blood sample, including cell counting, protein/enzyme and pathogen detection. ChipCare’s solution to this problem is an integrated point-of-care testing and monitoring system to address the current clinical challenges in both resource rich and resource limited settings. It combines patient identification, blood testing, communication, and external quality management protocol. It is also a platform system that can be used to test different diseases from a single drop of blood.
Flatfab offers software that facilitates the design and fabrication of 3D objects, bridging the gap between digital modeling and traditional craftsmanship. By allowing users to imagine in 3D while working in 2D, Flatfab addresses the challenges of 3D printing, which can be costly and time-consuming, particularly for complex, small-scale projects. The software supports various fabrication methods, including laser cutting and CNC machining, rather than relying solely on 3D printers. With features like interactive verification and real-time model testing, Flatfab empowers designers and hobbyists to work with a range of materials, such as paper, plastic, wood, steel, and stone, enabling them to create intricate 3D objects efficiently.
Nvest is an Internet platform that helps people become smarter investors. Anyone is free to share investment opinions. Nvest evaluates people’s credibility based on the accuracy of their opinions because actual performance speaks louder than credentials. Nvest is currently focusing on stock markets, and will be expanded to many possible investment types. People can express their opinions as buy and sell ratings. The accuracy of each opinion depends on its correctness, magnitude of impact and industry. Nvest wants to consolidate and present only the very valuable investment information to retail investors at the right time. People will be able to access Nvest with any Internet devices. Visit http://www.nvest.me for open beta!
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
Vasomune Therapeutics is a private biotechnology company developing therapies to target diseases associated with blood vessel (vascular) dysfunction and destabilization. The inner most layer of blood vessels is made up of individual endothelial cells that regulate the passage of immune and inflammatory cells to a site of injury. In many different disease states, dysfunctional vasculature results in an exaggerated inflammatory response. Vascular dysfunction can lead to, or exacerbate many different diseases such as cardiovascular, renal, pulmonary and oncology. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that has demonstrated positive therapeutic effect in many different diseases associated with vascular dysfunction. Vasomune Therapeutics, spun out of MaRS Innovation, Sunnybrook Hospital and Health Sciences Centre at the University of Toronto in 2012, is translating a strong foundation of academic science into clinical practice. Vasomune’s initial programs focus on targeting acute and chronic diseases of the kidney. The lead development program takes aim at treating Acute Kidney Injury (AKI), a significant unmet medical need. While several distinct clinical paths exist for the development of Vasculotide, the decision to pursue AKI is based on a strong, third-party validated preclinical data set and converging evidence that vascular dysfunction lies at the core of AKI.
Granata's software platform provides real-time optimization and scenario analysis capabilities for large-scale, data-driven marketing problems and group/organizational decision-making. Companies use the technology to amplify the value of machine learning and analytics by distilling the insights produced by multiple analyses and focusing on the factors relevant to global enterprise objectives.
Whirlscape is a company focused on enhancing the texting experience through innovative technology. They offer a mobile keyboard application that streamlines typing by minimizing the keyboard to a one-line format, allowing users to view more of their screen and type more efficiently. The application is designed to work across various device sizes, ensuring a user-friendly experience. Additionally, Whirlscape utilizes machine learning to develop predictive messaging capabilities, creating natural language models that anticipate user input, including text, emojis, stickers, and GIFs. This combination of features aims to improve communication by making it faster and more expressive.
Product Crowdfunding in 2013
WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.
ChipCare’s mission is to bring lab-based medical tests to patients, enabling every person around the world to have easy access to state-of-the-art blood tests. The envisioned product entails two components: handheld reader and disposable test slide. The revenue will mainly be generated from sales of disposable test slides (consumables). Our proprietary detection technique enables testing of multiple diseases from a single drop of blood sample, including cell counting, protein/enzyme and pathogen detection. ChipCare’s solution to this problem is an integrated point-of-care testing and monitoring system to address the current clinical challenges in both resource rich and resource limited settings. It combines patient identification, blood testing, communication, and external quality management protocol. It is also a platform system that can be used to test different diseases from a single drop of blood.
BlueDot Inc. is a data analytics company based in Toronto, Canada, specializing in infectious disease monitoring and response. Founded in 2008 and formerly known as BioDiaspora Inc., BlueDot employs a combination of artificial intelligence and human expertise to analyze over 190 infectious diseases worldwide. The company provides critical insights by integrating various datasets, including disease outbreaks, healthcare facilities, local mobility patterns, animal populations, and climate data. Its early warning system helps public and private organizations identify potential infectious disease threats, allowing them to respond effectively without overreacting or underreacting. By delivering comprehensive data analytics solutions, BlueDot aims to enhance global preparedness against infectious diseases.
Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application that enhances the grading and assessment process for educators by bridging paper-based and digital formats. The platform is designed to facilitate both online and in-class assessments, allowing teachers to grade assignments more efficiently while offering constructive feedback to students. By leveraging artificial intelligence, Crowdmark aims to improve learning outcomes and redefine assessment as a constructive dialogue between educators and students. The service is utilized by instructors across various educational levels, including primary, secondary, and tertiary institutions, both in Canada and internationally. Additionally, Crowdmark's system generates valuable insights into grading and learning performance, contributing to an enhanced educational experience.
Treata Smart Solutions is a company based in Toronto, Ontario, that specializes in caregiving technology for memory-impaired adults. Founded in 2012, it offers three innovative products: The Smart Lost Item Finder, The Smart Wandering Assistant, and The Smart Reminder. These devices leverage existing smartphone technology, enhanced with patent-pending hardware and software, to assist caregivers in monitoring the well-being of elderly individuals. The company's solutions aim to improve safety by providing real-time location information and alerts, ensuring that caregivers are promptly informed if a loved one with memory difficulties becomes lost or encounters any issues.
Root2Crown is developing hardware and software solutions to make it easier to conduct and communicate required dental risk assessment processes while increasing the efficiency, reliability and availability of dental health assessment and diagnosis for dental schools, practices and the general public.
TrendMD provides article recommendations for doctors. They partner with scientific publishers such Elsevier and Oxford University Press and have them add a line of their JavaScript code to their journal websites so that they can show 10 similar article links at the bottom of each page. Their mission is to accelerate the rate at which humanity's knowledge advances, by matching readers with the right articles. They serve 500 million recommendations to more than 60 million readers per month and are nearing profitability after recently graduating from Y Combinator -- the startup accelerator that incubated Reddit, Dropbox, and Airbnb.
Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application that enhances the grading and assessment process for educators by bridging paper-based and digital formats. The platform is designed to facilitate both online and in-class assessments, allowing teachers to grade assignments more efficiently while offering constructive feedback to students. By leveraging artificial intelligence, Crowdmark aims to improve learning outcomes and redefine assessment as a constructive dialogue between educators and students. The service is utilized by instructors across various educational levels, including primary, secondary, and tertiary institutions, both in Canada and internationally. Additionally, Crowdmark's system generates valuable insights into grading and learning performance, contributing to an enhanced educational experience.
XLV Diagnostics Inc., located in Thunder Bay, Canada, specializes in the development and manufacturing of low-cost, next-generation digital mammography machines aimed at improving access to breast cancer screening in emerging markets such as China, India, and Brazil. The company utilizes innovative X-ray light valve technology to create mammography detectors that are integrated into custom-designed digital mammography systems. This approach allows XLV Diagnostics to provide affordable and high-quality early-stage breast cancer detection services to clients in developing countries, addressing the growing demand for effective diagnostic technology in regions where breast cancer cases are increasing faster than access to screening options.
eQOL is focused on transforming chronic care by shifting it from hospital settings to home environments, addressing the needs of an aging population and increasing healthcare demands. The company has developed a patient-centric medical platform that empowers individuals to manage their daily clinical tasks independently. By leveraging innovative technologies and processes, eQOL aims to enhance the quality of care while promoting patient independence. This approach not only optimizes overall efficiency but also reduces healthcare delivery costs, making the medical process less intimidating for clients. Ultimately, eQOL's mission is to build the necessary infrastructure and solutions that facilitate effective self-care in the home.
Kaypok specializes in developing advanced unstructured text analytics software that enables enterprises to extract valuable insights from various data sources, such as social media, internal data, customer surveys, emails, and blogs. By analyzing this unstructured data, Kaypok provides businesses with actionable knowledge about customer sentiments and the underlying factors influencing analytics. The company's technology enhances user experience and optimizes enterprise applications by transforming complex information into usable insights, thereby supporting organizations in making informed decisions based on comprehensive data analysis.
Bedside Clinical Systems (BCS) facilitates the deployment of innovations in healthcare supporting clinicians in providing safer and more effective care.
CoursePeer is a developer of a cloud-based suite designed to enhance learning, collaboration, and decision-making in both academic and corporate environments. Its highly scalable and integrated tools support a range of activities, including blended learning, video content delivery, quizzes, and live interactions, all within a social network framework that encourages user engagement. The academic version targets universities and colleges, enabling professors to effectively deliver content and foster communication among students while facilitating assessments and course content reviews for accreditation purposes. The corporate version focuses on employee training and certification, providing capabilities for intranet use and advanced performance management. Overall, CoursePeer's solutions aim to empower institutions and businesses to improve their performance and productivity.
Kapplex Inc. is a Toronto-based company that designs, develops, manufactures, and markets point-of-care diagnostic platforms aimed at diagnosing common infectious diseases and cancer. Established in 2012, Kapplex specializes in providing instruments and consumables for use in retail clinics, doctors' offices, urgent care units, and emergency rooms. The company's innovative technology is built on a proprietary Digital Microfluidic (DMF) platform, which simplifies and automates traditional sample preparations and analyses on a single, cost-effective chip. This advancement allows clinicians to rapidly and accurately diagnose diseases during a patient's first visit, thereby improving treatment outcomes and reducing healthcare costs.
OtoSim was developed by a renowned multi-disciplinary team of clinicians, educators, and engineers. Drs. Forte and Campisi recognized the deficiencies that exist in current-day otoscopic training, pioneered the OtoSim device to resolve the problem and proved its value through a scientific study. Enlisting commercialization support from MaRS Innovation and The Hospital for Sick Children (SickKids), the multi-disciplinary team engineered the device and developed the software to create OtoSim
Xagenic Inc., a Toronto, Canada-based molecular diagnostics company developing new technology for decentralized, rapid diagnostic testing, and a true point-of-care platform. Our aim is to enable on-demand, near-patient molecular testing, empowering clinicians in making treatment decisions for their patients at the time of the first consultation. This will dramatically improve patient care and reduce health care costs. Xagenic has adapted this technology to permit rapid, enzyme-free detection of nucleic acids from clinical samples. We are commercializing a simple and fully automated technology platform that will enable widespread decentralized diagnostic testing to be performed outside of clinical laboratories. Our team is developing infectious disease tests that will allow the detection of a variety of analytes in situations where rapid test turnaround will provide clinically actionable results.